News

July 23, 2019

NantKwest Launches Phase 1 Trial to Assess Investigational Cell Therapy for B-cell Lymphomas

News

NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows ... Read more

July 19, 2019July 19, 2019

Affimed Trial Updates Support AFM13 Use for Certain CD30-positive Lymphomas

News

Updated results from two clinical trials support the potential of AFM13, an investigational immunotherapy being developed by Affimed, in combination with Merck‘s Keytruda (pembrolizumab) for patients with Hodgkin’s lymphoma, ... Read more

July 18, 2019

Localized and Superficial Brain PCNS Lymphomas May Benefit from Surgery, Study Reviews Suggest

News

Certain patients with primary central nervous system (PCNS) lymphoma, a rare type of brain cancer, may benefit more from having surgery to remove their tumor than following the current ... Read more

July 16, 2019

FDA Grants Fast Track Status to Investigational Compound CLR 131 for DLBCL

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large ... Read more

July 12, 2019July 12, 2019

Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL

News

Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero ... Read more

July 11, 2019

TG Therapeutics to Seek Accelerated Approval of Umbralisib for Marginal Zone Lymphoma

News

After positive feedback from the U.S. Food and Drug Administration, TG Therapeutics is planning to pursue accelerated approval for umbralisib (TGR-1202) as a treatment for patients with marginal zone lymphoma ... Read more

July 9, 2019

REGN1979 Eliminated Cancer in Most Non-Hodgkin’s Lymphoma Patients in Phase 1 Trial

News

Regeneron‘s bispecific antibody REGN1979 is showing outstanding clinical effectiveness in B-cell non-Hodgkin’s lymphoma patients who received prior treatments, including those who progressed after CAR T-cell therapies. The treatment completely ... Read more

July 2, 2019July 2, 2019

CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to ... Read more

June 28, 2019

X4 Pharmaceuticals, LLS Collaborate to Develop Mavorixafor to Treat Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals and The Leukemia & Lymphoma Society (LLS) have joined forces to accelerate the development of X4’s lead product candidate, mavorixafor, for the treatment of Waldenström’s macroglobulinemia, a ... Read more

June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. ... Read more

Pin It on Pinterest